Current strategies to minimize toxicity of oxaliplatin: Selection of pharmacogenomic panel tests

Anti-Cancer Drugs

Volumn 24, Issue 10, 2013, Pages 1069-1078

  Di Francia, Raffaele ^a   Siesto, Raffaella Stefania ^a   Valente, Daniela ^d   Del Buono, Andrea ^e   Pugliese, Sergio ^f   Cecere, Sabrina ^b   Cavaliere, Carla ^b   Nasti, Guglielmo ^c   Facchini, Gaetano ^b   Berretta, Massimiliano ^g  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Uro Gynaecologic Department   (Italy)

^c National Cancer Institute   (Italy)

^d Italian Association of Pharmacogenomics and Molecular Diagnostics   (Italy)

^e ASL Ce1   (Italy)

^f CETAC Research Center   (Italy)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

ABCC2; genotyping methods; GSTP1; neurotoxicity; oxaliplatin; pharmacogenomics

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; CALCIUM ION; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CARBAMAZEPINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CURCUMIN; FLUOROURACIL; FOLINIC ACID; GINKGO BILOBA EXTRACT; GLUTAMINE; GLUTATHIONE; HERBACEOUS AGENT; IRINOTECAN; MAGNESIUM ION; NEUROTROPIN; OXALIPLATIN; RALTITREXED; THIOCTIC ACID; VENLAFAXINE; XALIPRODEN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL EVALUATION; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG TOXICITY; DRUG WITHDRAWAL; DYSESTHESIA; DYSPHONIA; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INFUSION RATE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; STOMACH CARCINOMA;

ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84885378122     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000002     Document Type: Article

References (55)

1. Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, et al. Longterm neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012; 118: 5614-5622.
2. Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen. Pharmacogenomics J 2012; [Epub ahead of print].
3. Camilleri M, Saito YA. Pharmacogenomics in gastrointestinal disorders. Methods Mol Biol 2008; 448:395-412.
4. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, et al. Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 2008; 14:1059-1064.
5. Di Francia R, Siesto RS, Valente D, Spartà D, Berretta M. Pharmacogenomics panel test for prevention toxicity in patients who receive fluoropirimidine/oxaliplatin-based therapy. Eur Rev Med Pharmacol Sci 2012; 16:215-298.
6. Tirelli U, Berretta M, Bearz A, Carbone A. Grouping of molecularly targeted anti-cancer agents based on cost-effectiveness analysis. Eur Rev Med Pharmacol Sci 2011; 15:1355-1356.
7. Payne K, Shabaruddin FH. Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics 2010; 11:643-646.
8. Dhalla IA, Garner S, Chalkidou K, Littlejohns P. Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. Int J Technol Assess Health Care 2009; 25:272-280.
9. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30:1147-1158.
10. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23.
11. Hah SS, Stivers KM, Devere White RW, Henderson PT. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as De termined by accelerator mass spectrometry. Chem Res Toxicol 2006; 19:622-626.
12. Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon MS, Kaube H, et al. Repair capacity for platinum-DNA adducts De termines the severity of cisplatin-induced peripheral neuropathy. J Neurosci 2007; 27:9451-9457.
13. Berretta M, Lleshi A, Di Benedetto F, Bearz A, Spina M, Tirelli U. Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients. Ann Oncol 2006; 17:1176-1177.
14. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
15. Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, Massuti B, Aparicio J, et al. Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A phase II study of the Spanish cooperative group for the treatment of digestive tumors. Clin Colorectal Cancer 2012; 11:200-206.
16. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: Oxaliplatin. Oncologist 2004; 9:8-12.
17. Berretta M, Taibi R, Bearz A, La Mura N, Berretta S, Tirelli U, et al. Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy. J Chemother 2004; 16:595-598.
18. Berretta M, Bearz A, Frustaci S, Talamini R, Lombardi D, Fratino L, et al. FOLFOX2 in the treatment of advanced colorectal cancer: A comparison between elderly and middle aged patients. J Chemother 2008; 20: 503-508.
19. Berretta M, Lleshi A, Cappellani A, Bearz A, Spina M, Talamini R, et al. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of patients with colorectal cancer and HIV infection. Curr HIV Res 2010; 8:218-222.
20. Berretta M, Di Benedetto F, Bearz A, Simonelli C, Martellotta F, Del Ben C, et al. FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: A report of five cases and review of the literature. Cancer Invest 2008; 26:610-614.
21. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25:1247-1254.
22. Braun MS, Richman SD, Thommpson L, Daly CL, Meade AM, Adlard JW, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. J Clin Oncol 2009; 27:5519-5528.
23. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: A systemic review and meta-analysis. Clin Cancer Res 2011; 17:1632-1640.
24. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003; 1:162-166.
25. Balboa E,Duran G, LamasMJ, Gomez-Caamano A, Celeiro-Munoz C, Lopez R, et al. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: High incidence of somatic mutations and their relation with response. Pharmacogenomics 2010; 11:747-761.
26. Kim JG, Chae YS, Sohn SK, Moon JH, Ryoo HM, Bae SH, et al. Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T >C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. Cancer Chemother Pharmacol 2009; 64:953-960.
27. Gamelin L, Capitain O, Morel A, Dumont A, Traore S, Anne le B, et al. Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway. Clin Cancer Res 2007; 13:6359-6368.
28. Durand JP, De planque G, Montheil V, Gornet JM, Scotte F, Mir O, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebocontrolled phase III trial. Ann Oncol 2012; 23:200-205.
29. Wang WS, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist 2007; 12:312-319.
30. Zhang RX, Lu ZH, Wan DS, Wu XJ, Ding PR, Kong LH, et al. Neuroprotective effect of neurotropin on chronic oxaliplatin-induced neurotoxicity in stage II and stage III colorectal cancer patients: Results from a prospective, randomised, single-centre, pilot clinical trial. Int J Colorectal Dis 2012; 27:1645-1650.
31. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20:3478-3483.
32. Al Moundhri MS, Al-Salam S, Al Mahrouqee A, Beegam S, Ali BH. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: Some behavioral, biochemical, and histopathological studies. J Med Toxicol 2012; 9:25-33.
33. Mahdy HM, Tadros MG, Mohamed MR, Karim AM, Khalifa AE. The effect of Ginkgo biloba extract on 3-nitropropionic acid-induced neurotoxicity in rats. Neurochem Int 2011; 59:770-778.
34. Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, et al. The Kampo medicine, goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 2011; 16:322-327.
35. Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncol 2006; 7:288.
36. Von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K, Kullmann F, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007; 25:173-180.
37. Gedlicka C, Scheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002; 20:3359-3361.
38. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: A promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001; 12:421-422.
39. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12:3050-3056.
40. Etienne-Grimaldi MC, Milano G, Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol 2010; 69:58-66.
41. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010; 28: 3227-3233.
42. Fontana L, De lort L, Joumard L, Rabiau N, Bosviel R, Satih S, et al. Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res 2009; 29:1631-1635.
43. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicintype induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008; 18:357-365.
44. Tiseo M, Bordi P, Bortesi B, Boni L, Baldini E, Grossi F, et al. ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 2013; 108:1695-1703.
45. Grothey A, Sargent DJ. New lessons from old chemotherapy in colorectal cancer. J Clin Oncol 2008; 26:4532-4534.
46. Argyriou AA, Cavaletti G, Briani C, Velasco R, Bruna J, Campagnolo M, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in patients with colorectal cancer. Cancer 2013; 119:438-444.
47. Kurniali PC, Luo LG, Weitberg AB. Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology (Williston Park) 2010; 24:289-292.
48. Knijn N, Tol J, Koopman M,Werter MJ, Imholz AL, Valster FA, et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47:369-374.
49. Van Den Akker-van Marle ME, Gurwitz D, De tmar SB, Enzing CM, Hopkins MM, Gutierrez De Mesa E, et al. Cost-effectiveness of pharmacogenomics in clinical practice: A case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7: 783-792.
50. Di Francia R, Berretta M, Catapano O, Canzoniero LM, Formisano L. Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: Costs, methods and applications. Clin Chem Lab Med 2011; 49:1105-1111.
51. Di Francia R, Frigeri F, Berretta M, Cecchin E, Orlando C, Pinto A, et al. De cision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics. Clin Chem Lab Med 2010; 48:447-459.
52. Di Francia R, Valente D, Catapano O, Rupolo M, Tirelli U, Berretta M. Knowledge and skills needs for health professions about pharmacogenomics testing field. Eur Rev Med Pharmacol Sci 2012; 16:781-788.
53. Tirelli U, Berretta M, Spina M, Michieli M, Lazzarini R. Oncologic drug shortages also in Italy. Eur Rev Med Pharmacol Sci 2012; 16:138-139.
54. Berretta M, Lleshi A, Fisichella R, Berretta S, Basile F, Li Volti G, et al. The role of nutrition in the development of esophageal cancer: what do we know' Front Biosci (Elite Ed) 2012; 4:351-357.
55. Berretta M, Cappellani A, Lleshi A, Di Vita M, Lo Menzo E, Bearz A, et al. The role of diet in gastric cancer: Still an open question. Front Biosci 2012; 17:1640-1647.